| Market Cap | 12.19B 10.5B 9.86B 9.02B 16.87B 1,152B 16.93B 117B 45.29B 591B 45.78B 44.79B 1,905B | P/E 2026 * |
54.8x | P/E 2027 * | 26.3x |
|---|---|---|---|---|---|
| Enterprise Value | 12.19B 10.5B 9.86B 9.02B 16.87B 1,152B 16.93B 117B 45.29B 591B 45.78B 44.79B 1,905B | EV / Sales 2026 * |
10.6x | EV / Sales 2027 * | 7.15x |
| Free-Float |
65.9% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Corcept Therapeutics
| 1 day | +0.16% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 31/12/1998 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 28/02/2021 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 31/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 31/12/1998 |
James Wilson
CHM | Chairman | 82 | 31/12/1998 |
David Mahoney
BRD | Director/Board Member | 71 | 30/06/2004 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +13.02% | - | - | 12.19B | |
| -0.88% | -2.27% | +55.78% | +106.31% | 1,034B | |
| -1.15% | +3.56% | +54.62% | +71.50% | 671B | |
| -1.44% | -0.65% | +21.05% | +73.05% | 460B | |
| +0.14% | -1.92% | +32.47% | +37.60% | 353B | |
| -1.33% | +3.96% | +25.71% | +45.03% | 309B | |
| -1.15% | -0.89% | -1.67% | +12.21% | 255B | |
| -1.55% | +0.05% | +54.04% | +70.32% | 240B | |
| -0.88% | +1.24% | -18.03% | -54.06% | 207B | |
| -0.15% | +1.43% | +33.64% | +96.99% | 188B | |
| Average | -0.35% | +1.27% | +28.62% | +50.99% | 412.97B | |
| Weighted average by Cap. | -0.20% | +1.04% | +37.27% | +66.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.15B 987M 927M 848M 1.59B 108B 1.59B 10.96B 4.26B 55.51B 4.3B 4.21B 179B | 1.7B 1.47B 1.38B 1.26B 2.36B 161B 2.37B 16.31B 6.33B 82.57B 6.4B 6.26B 266B |
| Net income | 242M 208M 195M 179M 334M 22.82B 335M 2.31B 897M 11.7B 907M 887M 37.73B | 594M 511M 480M 439M 821M 56.09B 824M 5.68B 2.2B 28.75B 2.23B 2.18B 92.74B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
